0JDI.L

Ionis Pharmaceuticals, Inc. [0JDI.L] Stock Forecast

Q: What is Ionis Pharmaceuticals, Inc. stock symbol ?

Ionis Pharmaceuticals, Inc. is a US stock, located in Carlsbad of Ca and trading under the symbol 0JDI.L

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

0JDI.L Stock Summary

Earnings have grown 34.1% per last year.

Has a high level of debt. Debt-to-Equity ratio of 4.65 is considered high.

Earnings are expected to fall -100% next year

EPS has been decreasing for the past 3 years (Yearly statements)

Profit margins (-0.67%) are lower than the previous year (-0.47%)

0JDI.L has less than 1 year of cash runway

Top 10 Correlated Stocks

0JDI.L

In the News

0JDI.L Financial details

Company Rating

Neutral

Market Cap

6.16B

Income

-366.02M

Revenue

788.14M

Book val./share

2.69

Cash/share

16.23

Dividend

Dividend %

Employees

927

Optionable

Shortable

Yes

Earnings

01 May 2024

P/E

-18.19

Forward P/E

PEG

-5.22

P/S

12.12

P/B

23.61

P/C

2.51

P/FCF

-13.1

Quick Ratio

5.9

Current Ratio

6.39

Debt / Equity

4.65

LT Debt / Equity

4.51

EPS (TTM)

-2.56

EPS next Y

EPS next Q

EPS this Y

34.74%

EPS next Y

EPS next 5Y

EPS last 5Y

NAN%

Revenue last 5Y

-6.84%

Revenue Q/Q

125.37%

EPS Q/Q

-93.93%

SMA20

-2.33%

SMA50

-17.65%

SMA100

-12.5%

Inst Own

Inst Trans

ROA

-14%

ROE

-91%

ROC

-0.22%

Gross Margin

-56%

Oper. Margin

-90%

Profit Margin

-67%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

33.21-53.945

52W High

-23.21%

52W Low

+23.33%

RSI

Rel Volume

0.01

Avg Volume

351

Volume

Perf Week

-5.17%

Perf Month

-8.76%

Perf Quarter

-12.9%

Perf Half Y

-16.24%

Beta

0.402

Volatility

0.58%, 0.99%

Prev Close

-1.52%

Price

40.7

Change

-1.74%

0JDI.L Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	8.02	5.22	5.75	4.14	5.5
Net income per share	2.12	-3.18	-0.2	-1.9	-2.56
Operating cash flow per share	2.47	0.26	0.22	-1.93	-2.15
Free cash flow per share	2.21	-0.04	0.09	-2.08	-2.34
Cash per share	17.92	13.6	15.11	14.08	16.32
Book value per share	10.51	5.32	5.47	4.04	2.7
Tangible book value per share	11.85	5.12	5.27	4.04	2.7
Share holders equity per share	10.51	5.32	5.47	4.04	2.7
Interest debt per share	5.86	6.8	8.8	8.45	13.11
Market cap	4.35B	4.34B	4.38B	5.21B	7.17B
Enterprise value	4.46B	4.88B	4.77B	6.31B	8.73B
P/E ratio	14.68	-9.77	-153.31	-19.33	-19.56
Price to sales ratio	3.88	5.95	5.41	8.88	9.1
POCF ratio	12.59	120.93	142.35	-19	-23.3
PFCF ratio	14.07	-841.84	339.92	-17.7	-21.36
P/B Ratio	2.96	5.84	5.68	9.1	18.53
PTB ratio	2.96	5.84	5.68	9.1	18.53
EV to sales	3.97	6.7	5.88	10.74	11.09
Enterprise value over EBITDA	11.67	-31.52	-448.54	-16.25	-26.37
EV to operating cash flow	12.89	136.03	154.75	-22.98	-28.4
EV to free cash flow	14.4	-946.96	369.53	-21.41	-26.03
Earnings yield	0.07	-0.1	-0.01	-0.05	-0.05
Free cash flow yield	0.07	0	0	-0.06	-0.05
Debt to equity	0.52	1.26	1.6	2.08	4.65
Debt to assets	0.24	0.39	0.47	0.47	0.6
Net debt to EBITDA	0.27	-3.5	-35.94	-2.82	-4.73
Current ratio	9.97	3.56	9.75	7.07	5.9
Interest coverage	7.5	-18.09	-3.23	-50.5	-4.34
Income quality	1.17	-0.08	-1.08	1.02	0.84
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	-0.58	-0.04	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0.41	0.73	0.79	1.42	1.14
Intangibles to total assets	0.01	0.01	0.01	0	0
Capex to operating cash flow	-0.1	-1.14	-0.58	0.07	0.09
Capex to revenue	-0.03	-0.06	-0.02	-0.03	-0.04
Capex to depreciation	-2.27	-2.39	-0.92	-0.91	-1.25
Stock based compensation to revenue	0.13	0.32	0.15	0.17	0
Graham number	22.38	19.52	5	13.15	12.47
ROIC	0.14	-0.36	-0.01	-0.22	-0.16
Return on tangible assets	0.09	-0.19	-0.01	-0.11	-0.12
Graham Net	7.26	2.3	2.48	0.47	-1.25
Working capital	2.45B	1.53B	2.1B	1.89B	2.19B
Tangible asset value	1.66B	715.35M	742.73M	572.89M	386.69M
Net current asset value	1.17B	484.23M	505.1M	241.71M	38.47M
Invested capital	0.52	1.26	1.6	2.08	4.65
Average receivables	37.9M	69.62M	69.05M	43.72M	61.66M
Average payables	22.36M	16.63M	14.55M	14.91M	21.97M
Average inventory	13.38M	20.07M	23.39M	23.42M	25.23M
Days sales outstanding	20.49	38.14	27.88	15.87	45.31
Days payables outstanding	287.78	215.67	142.92	180.59	300.33
Days of inventory on hand	325.63	275.44	297.82	222.03	328
Receivables turnover	17.81	9.57	13.09	23	8.06
Payables turnover	1.27	1.69	2.55	2.02	1.22
Inventory turnover	1.12	1.33	1.23	1.64	1.11
ROE	0.2	-0.6	-0.04	-0.47	-0.95
Capex per share	-0.26	-0.29	-0.13	-0.14	-0.2

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	1.07	0.91	1.32	1.01	2.26
Net income per share	-0.37	-0.87	-0.6	-1.03	-0.06
Operating cash flow per share	-1.41	-0.94	-0.68	-0.76	0.23
Free cash flow per share	-1.45	-1.02	-0.77	-0.78	0.23
Cash per share	14.07	16.44	16.67	15.6	16.23
Book value per share	4.03	3.41	2.99	2.2	2.69
Tangible book value per share	4.03	3.41	2.99	2.2	2.69
Share holders equity per share	4.03	3.41	2.99	2.2	2.69
Interest debt per share	8.39	12.01	12.96	12.73	12.63
Market cap	5.22B	5.01B	5.88B	6.52B	7.21B
Enterprise value	6.31B	6.57B	7.46B	8.15B	8.77B
P/E ratio	-25.09	-10.07	-17.22	-11.06	-200.16
Price to sales ratio	34.33	38.35	31.19	45.23	22.17
POCF ratio	-26.07	-37.36	-60.35	-59.83	219.25
PFCF ratio	-25.43	-34.35	-53.2	-58.1	219.07
P/B Ratio	9.11	10.29	13.72	20.68	18.63
PTB ratio	9.11	10.29	13.72	20.68	18.63
EV to sales	41.52	50.34	39.6	56.48	27
Enterprise value over EBITDA	-31.4	-60.54	-88.28	-59.16	-22.61K
EV to operating cash flow	-31.53	-49.04	-76.62	-74.71	266.96
EV to free cash flow	-30.76	-45.09	-67.55	-72.56	266.74
Earnings yield	-0.01	-0.02	-0.01	-0.02	0
Free cash flow yield	-0.04	-0.03	-0.02	-0.02	0
Debt to equity	2.08	3.49	4.28	5.71	4.65
Debt to assets	0.47	0.59	0.62	0.61	0.6
Net debt to EBITDA	-5.44	-14.42	-18.75	-11.79	-4.04K
Current ratio	7.07	9.81	9.09	6.39	5.9
Interest coverage	-120.16	-6.67	-4.52	-6.52	-0.27
Income quality	3.85	1.08	1.14	0.74	-3.65
Dividend Yield	0	0	0	0	0
Payout ratio	-0.01	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	2.03	1.52	1.22	1.49	0.79
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.03	0.09	0.13	0.03	0
Capex to revenue	-0.03	-0.09	-0.07	-0.02	0
Capex to depreciation	-0.71	-2.09	-2.3	-0.58	0
Stock based compensation to revenue	0.17	0.21	0.14	0.18	0
Graham number	5.77	8.17	6.34	7.14	1.94
ROIC	-0.13	-0.05	-0.04	-0.07	-0.01
Return on tangible assets	-0.02	-0.04	-0.03	-0.05	0
Graham Net	0.47	-0.21	-0.86	-1.84	-1.24
Working capital	1.89B	2.28B	2.33B	2.18B	2.19B
Tangible asset value	572.89M	486.57M	428.3M	315.46M	386.69M
Net current asset value	241.71M	143.97M	73.92M	-33.86M	38.47M
Invested capital	2.08	3.49	4.28	5.71	4.65
Average receivables	16.09M	19.73M	20.94M	85.16M	120.07M
Average payables	19.23M	14.21M	17.26M	14.82M	15.82M
Average inventory	21.34M	22.12M	23.87M	25.59M	27.03M
Days sales outstanding	15.12	9.59	13.35	88.85	27.08
Days payables outstanding	146.24	135.98	262.81	64.94	272
Days of inventory on hand	179.8	287.52	279.41	296.46	297.06
Receivables turnover	5.95	9.38	6.74	1.01	3.32
Payables turnover	0.62	0.66	0.34	1.39	0.33
Inventory turnover	0.5	0.31	0.32	0.3	0.3
ROE	-0.09	-0.26	-0.2	-0.47	-0.02
Capex per share	-0.04	-0.08	-0.09	-0.02	0

0JDI.L Frequently Asked Questions

What is Ionis Pharmaceuticals, Inc. stock symbol ?

Ionis Pharmaceuticals, Inc. is a US stock , located in Carlsbad of Ca and trading under the symbol 0JDI.L

What is Ionis Pharmaceuticals, Inc. stock quote today ?

Ionis Pharmaceuticals, Inc. stock price is $40.7 today.

Is Ionis Pharmaceuticals, Inc. stock public?

Yes, Ionis Pharmaceuticals, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 351
Market Capitalization 6.16B
Employee 927
CEO Dr. Brett P. Monia Ph.D.
Headquarters Carlsbad,CA,US
IPO Date 2018-01-29
Website https://www.ionispharma.com

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.